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Introduction: In contrast with the frequency distribution of chronic obstructive pulmonary 
disease (COPD) stages in the population, in which the majority of the patients is classiﬁ  ed as 
GOLD 2, much less information is available on the prevalence and implications of systemic 
manifestations in less severe patients relative to GOLD 3 and 4.
Aim: To characterize local and systemic impairment in relation to disease burden in a group 
of GOLD 2 COPD patients (n = 127, forced expiratory volume in one second (SD): 67 (11)% 
pred) that were eligible for the Interdisciplinary Community-based COPD management 
(INTERCOM) trial.
Methods: Patients were included for this lifestyle program based on a peak exercise capacity 
(Wmax) 70% of predicted. Metabolic and ventilatory response to incremental cycle ergometry, 
6 minute walking distance (6MWD), constant work rate test (CWR), lung function, maximal 
inspiratory pressure (Pimax), quadriceps force (QF), quadriceps average power (QP) (isokinetic 
dynamometry), handgrip force (HGF) and body composition were measured. Quality of life 
(QoL) was assessed by the St. George’s Respiratory Questionnaire (SGRQ) and dyspnea by the 
modiﬁ  ed Medical Research Council (MRC) dyspnea scale. Exacerbations and COPD-associated 
hospital admissions in 12 months prior to the start of the study were recorded. Burden of disease 
was deﬁ  ned in terms of exercise capacity, QoL, hospitalization, and exacerbation frequency. 
GOLD 2 patients were compared with reference values and with GOLD 3 patients who were 
also included in the trial.
Results: HGF (77.7 (18.8) % pred) and Pimax (67.1 (22.5)% pred) were impaired in GOLD 2, 
while QF (93.5 (22.5)% pred) was only modestly decreased. Depletion of FFM was present 
in 15% of weight stable GOLD 2 patients while only 2% had experienced recent involuntary 
weight loss. In contrast to Wmax, submaximal exercise capacity, muscle function, and body 
composition were not signiﬁ  cantly different between GOLD 2 and 3 subgroups. Body mass 
index and fat-free mass index were signiﬁ  cantly lower in smokers compared to ex-smokers. In 
multivariate analysis, QF and diffusing capacity (DLco) were independently associated with 
Wmax and 6 MWD in GOLD 2 while only 6 MWD was identiﬁ  ed as an independent determinant 
of health-related QoL. HGF was an independent predictor of hospitalization.
Conclusions: This study shows that also in patients with moderate COPD, eligible for a 
lifestyle program based on a decreased exercise capacity, systemic impairment is an important 
determinant of disease burden and that smoking affects body composition.
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Introduction
The burden of chronic obstructive pulmonary disease (COPD) is projected to increase 
excessively in the next decade (Murray et al 1997). Disability-adjusted life years lost will International Journal of COPD 2008:3(3) 444
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dramatically increase as COPD is expected to move from the 
12th rank in 2000 to the 5th rank in 2020 (Hurd 2000). A major 
component of disability is an impaired exercise capacity. In 
severe COPD systemic manifestations such as peripheral 
skeletal muscle weakness and muscle wasting are important 
determinants of impaired exercise performance (Gosselink 
et al 1996; Wouters 2002). Also in severe COPD, the relation 
between muscle dysfunction and the burden of the disease has 
been clearly established. Several studies have shown that low 
body mass index (BMI) and fat free mass (FFM), as marker 
of muscle mass, are independent predictors of mortality in 
patients with severe COPD (Gray-Donald et al 1996; Landbo 
et al 1999; Schols et al 2005). Muscle function has been iden-
tiﬁ  ed as a determinant of utilization of health care resources 
(Decramer et al 1997). Muscle wasting and muscle dysfunction 
are partly reversible by pulmonary rehabilitation (Bourbeau 
et al 2003; Grifﬁ  ths et al 2001; Nici et al 2006).
In contrast with the frequency distribution of COPD 
stages in the population, where most diagnosed patients are 
staged GOLD 2 (Hoogendoorn et al 2006), little information 
is available on the prevalence and implications of systemic 
manifestations in these less severe COPD. It is therefore 
important to determine, whether the concept of COPD as a 
systemic disease can be extended to less severe stages of the 
disease. We hypothesized that in moderate COPD patients 
with an impaired exercise capacity, muscle wasting and weak-
ness would also be present and would contribute to disease 
burden. This would provide a rationale for the application of 
lifestyle programs that encourage the incorporation of exercise 
training into daily life, provide smoking cessation support, 
improve dietary intake, provide psychosocial support, and 
stimulate self-management even in earlier disease stages. To 
assess the cost-effectiveness of an interdisciplinary commu-
nity-based COPD management program that includes all the 
above mentioned elements of a lifestyle program, we started 
the Interdisciplinary Community-based COPD management 
(INTERCOM) trial, a randomized controlled trial. Aim of the 
present study was to characterize local and systemic impair-
ment in the patients that were enrolled in this trial. Further-
more, we aimed to identify factors independently associated 
with an increased burden of COPD in these patients where 
burden was deﬁ  ned in terms of impaired exercise capacity, 
quality of life (QoL), exacerbations, and hospitalizations.
Material and methods
Patients and setting
The INTERCOM trial recruited newly detected patients and 
patients with a history of COPD, medically treated at the 
department of respiratory medicine of two general hospitals 
in Eindhoven, the Netherlands. Patients were included when 
peak exercise capacity (Wmax) during an incremental cycle 
ergometer test was less than 70% of predicted normal values 
(Jones et al 1985). Patients who had prior rehabilitation and 
patients with serious comorbidity that precluded exercise 
were excluded. Patients were judged to be clinically stable 
at inclusion and pharmacotherapy had been optimized. All 
patients gave written informed consent for participation in the 
study. Ethical approval was granted by the Medical Ethical 
Committee of the Máxima Medical Centre.
Baseline assessments
Lung function
Forced expiratory volume in one second (FEV1) and inspi-
ratory capacity were derived from the ﬂ  ow volume curve 
with the use of a spirometer (Masterlab, Jaeger, Wurzburg, 
Germany). Diffusing capacity for carbon monoxide (DLco) 
was determined with the single breath method (Masterlab) 
(Quanjer 1993).
Body composition
Body weight was measured using digital scales (Seca, Vogel 
Halke, Hamburg, Germany). Height was measured using a 
wall mounted stadiometer with subjects standing barefoot. 
BMI was calculated as weight/height² (kg/m²). FFM was 
estimated with single-frequency (50 kHz) bioelectrical 
impedance analysis (Bodystat 1500, Bodystat Ltd. Douglas, 
Isle of Main, Britain). Resistance was measured with subjects 
in the supine position. FFM was calculated with the disease-
speciﬁ  c regression equation (Schols et al 1991). Depletion of 
fat free mass was deﬁ  ned as FFMI 15 (female)/16 (male) 
kg/m². Nutritional depletion was deﬁ  ned as BMI 21 and/or 
FFMI 15 (female)/16 (male) kg/m². Involuntary weight 
loss was deﬁ  ned as weight loss of at least 5% in one month 
or at least 10% in six months prior to admission to the COPD 
management program while the BMI was at most 25 kg/m². 
Fat mass was expressed as percentage of total body mass.
Respiratory and peripheral muscle function
Respiratory muscle function was assessed by measuring 
maximal inspiratory mouth pressure (Pi-max) according to 
the method of Black and Hyatt (Masterlab; Black et al 1969). 
The highest value of ﬁ  ve technically satisfactory measure-
ments was used for analysis. Pi-max values were recorded 
as positive values.
Peripheral muscle function was assessed by the handgrip 
force (HGF) and the isometric and isokinetic quadriceps force. International Journal of COPD 2008:3(3) 445
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Isometric HGF in pounds was measured with a hydraulic hand 
dynamometer (Yamar Preston). The force was measured three 
times in each hand. The highest value of the right hand was 
used in the analyses. Isometric and isokinetic quadriceps func-
tion were measured using a Biodex system 3 (New York, NY) 
dynamometer. Peak torque (QF) in Newton-meters (Nm) was 
measured at the dominant side, during a maximal isometric 
knee extension manoeuvre with the hip in 90° ﬂ  exion and the 
knee in 60° ﬂ  exion. The highest value of three attempts was 
used in the analysis. Average power (QP) in Watt (W) was 
measured during an isokinetic test at a speed of 60º (QP-60°) 
and 180°/second (QP-180°) during 5 and 10 contractions 
respectively from 0° till 90° knee ﬂ  exion.
Exercise capacity
Exercise capacity was measured using an incremental cycle 
exercise test, a constant work rate test (CWR) and a 6 minute 
walking test. The incremental exercise test and the CWR 
test were performed on an electro magnetically braked cycle 
ergometer (Corrival 1, Lode, Groningen, The Netherlands. 
Arterial blood samples were taken at rest and during the last 
minute from the forearm. Arterial oxygen tension (PaO2) 
and carbon dioxide pressure (PaCO2) were analyzed on a 
blood gas analyzer (ABL 800 ﬂ  ex, Radiometer, Copenhagen, 
Denmark). Measurements of pulmonary ventilation (VE) and 
respired fractions of oxygen uptake (VO2) and carbon dioxide 
output (VCO2) were obtained breath by breath (Oxycon α, 
Jaeger, Wurzburg, Germany). An individualized ramp proto-
col was used and the test was ended when the patient was not 
able to maintain the required pedalling frequency. Peak heart 
rate (HR) was calculated as 220 – age, and peak ventilatory 
minute ventilation (VE) was calculated as FEV1 × 37.5.
The CWR test was performed at 50% of the peak work 
rate (CWR 50%) during maximal 10 minutes. Thereafter the 
test was continued at 70% of peak work rate (CWR 70%) until 
exhaustion occurred. The 6 minutes walking test measured 
the distance walked during 6 minutes (6 MWD) in a 50-meter 
corridor in the hospital. The test was performed without 
encouragement and was repeated two times on nonconsecu-
tive days. The largest distance was used in the analysis.
Dyspnea
The degree of dyspnea was measured with the modiﬁ  ed 
Medical Research Council (MRC) dyspnea scale (Fletcher 
et al 1959; Bestall et al 1999).
Health-related QoL
Disease-speciﬁ  c QoL was assessed with the St. George’s 
Respiratory Questionnaire (SGRQ) (Jones et al 1992). The 
SGRQ is a 50-item self-administered questionnaire developed 
to measure the impact of asthma or COPD on health-related 
QoL and well-being. Responses can be aggregated into an 
overall score and three sub scores for ‘symptoms’, ‘activity’ 
and ‘impact’.
Exacerbation rate
An exacerbation was deﬁ  ned as an increase in respiratory 
symptoms that initiated treatment with oral corticosteroids 
and/or antibiotics. Exacerbations 12 months prior to the start 
of the study were taken into account. These exacerbations 
were self-reported.
Hospital admission rate
All COPD-related hospital admissions during a timeframe 
of 12 months before the patient’s entry into the trial were 
retrieved from the electronic hospital records.
Statistical analysis
Descriptive statistics of demographic and lung function char-
acteristics, exercise performance, body composition, muscle 
function, dyspnea, QoL, exacerbation, and hospitalization 
rate at baseline of the INTERCOM trial are provided and 
where possible compared to reference values to adequately 
describe the patient population in this trial. Because of limited 
availability of appropriate reference values, GOLD 2 patients 
were also compared to the GOLD 3 patients participating 
in the same trial using either Independent-Samples T-tests, 
nonparametric Mann-Whitney U-tests or Chi-Square tests. 
Differences between groups were also tested with multivari-
ate analysis of covariance (ANCOVA) adjusted for gender 
and smoking status.
In univariate analyses of variance, the association 
between Wmax, 6MWD, and SGRQ score on the one hand 
and functional variables on the other hand was assessed 
using ANCOVA with GOLD stage as a factor. This was 
followed by stepwise multiple regression analyses with 
Wmax, 6 MWD, and SGRQ score as dependent variables 
and all patient characteristics known to be related to these 
dependent variables in patients with more severe COPD. 
Differences between GOLD 2 patients with and without 
exacerbations or hospitalizations were compared with Inde-
pendent Samples T-test. Logistic regression analyses were 
performed to conduct univariate and multivariate analyses 
of the association between COPD-related exacerbations and 
hospital admissions as dependent variables and patient char-
acteristics previously found to be related to these variables 
as independent variables. Variables were removed from the International Journal of COPD 2008:3(3) 446
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regression equation when their p value was greater than 0.10. 
Furthermore the collinearity statistics of the independent 
variables in terms of tolerance were used to prevent high 
correlations between the variables in the regression model 
(Landis et al 1977). SPSS version 12 (SPSS Inc., Chicago, 
IL) was used for the computations.
Results
Patient enrolment
Figure 1 shows the patient enrolment scheme. Data of 180 
patients were included in this analysis. Of these 180 patients, 
127 (71%) had GOLD 2 COPD and 53 (29%) had GOLD 
3 COPD.
Included in the current analyses (n = 180)
Not GOLD 2–3 (n = 6)
Written informed consent (n = 199) 
Participants with baseline measurements (n = 186)
Referred for assessment (n = 355) 
Excluded (n = 156)
•W m a x   > 70% (n = 66)
• Comorbidity (n = 23)
• prior  rehabilitation (n = 25)
•F E V 1  ≥  80% (n = 8)
• Refused to participate (n = 34)
Withdrawn before baseline measurements (n = 13)
- Comorbidity (n = 3)
- Refused further participation (n = 9)
- Illness of family member (n=1)
Figure 1 Patient enrolment scheme.International Journal of COPD 2008:3(3) 447
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Pulmonary function, health-related 
QoL, dyspnea, exacerbations, 
and hospitalization
Table 1 compares the demographic and lung function char-
acteristics of the GOLD 2 and GOLD 3 patients, as well as 
the QoL, dyspnea, exacerbation, and hospitalization data. 
QoL was signiﬁ  cantly more impaired in GOLD 3 compared 
with GOLD 2.
Exacerbation frequency was signiﬁ  cantly higher in GOLD 3 
patients, but there was no difference between GOLD 2 and 
GOLD 3 patients in COPD-related hospital admissions.
Exercise performance, muscle function, 
and body composition
After adjustment for smoking status and gender, signiﬁ  cant 
differences between patients with GOLD 2 and patients with 
GOLD 3 were present in Wmax, peak minute ventilation, 
respiratory quotient (RQ), and carbon dioxide output, PaO2, 
PaCO2 at peak work rate. Wmax was signiﬁ  cantly (p  0.001) 
lower in patients with GOLD 3 (73 W, 47% predicted) than in 
patients with GOLD 2 (91 W, 67% predicted). As expected, 
peak minute ventilation and ventilatory reserve were signiﬁ  -
cantly lower in patients with GOLD 3 than in patients with 
GOLD 2. There were no differences in Vo2 peak/weight, peak 
heart rate, and heart rate reserve % predicted.
Despite a lower peak work rate in GOLD 3, submaximal 
exercise response (6 MWD and CWR-70%) was not signiﬁ  -
cantly different between GOLD 2 and GOLD 3. Muscle func-
tion was decreased in both GOLD 2 and GOLD 3 patients. 
However, QF was only slightly reduced, whereas the decrease 
of HGF, Pi-max, and Pe-max was clearly more outspoken. In 
36 GOLD 2 patients (28%) and 17 GOLD 3 patients (32%), 
QF was less than 80 % pred. No signiﬁ  cant differences in 
muscle function were found between patients with GOLD 
2 and patients with GOLD 3. HGF correlated well with QF 
(r = 0.72, p  0.01) and FFM (r = 0.56, p  0.01).
The FFMI was significantly lower in male patients 
with GOLD 3 compared with male patients with GOLD 
2 (17.0 kg/m² versus 17.8 kg/m², p  0.05). In GOLD 2 
depletion of FFM and involuntary weight loss was present 
in 21 (17%) patients. 19 (15%) patients were characterized 
by a depletion of FFM, 2 (2%) patients reported involuntary 
weight loss without depletion of FFM and in 1 patient BMI 
was 21 with normal FFM. Differences between smokers 
and ex-smokers were found in BMI (24.6 (SD 4.2) versus 
27.5 (SD 4.3), p  0.001), FFMI (16.7 (SD 1.9) versus 
17.6 (SD 1.8), p  0.01) and fat mass as percentage of 
total body mass (FM% weight) (31.6 (SD 6.6) versus 35.4 
(SD 6.8), p  0.01). 38 % of the smokers had a depletion of 
FFM versus 10 % of the ex-smokers (p  0.001).
Parameters associated with exercise 
capacity in GOLD 2
In univariate analysis, muscle function parameters (QF, QP-
60°, QP-180°, HGF, Pi-max) and DLco were signiﬁ  cantly 
(p  0.001) related to Wmax and the 6 MWD. In contrast, no 
signiﬁ  cant association between FEV1% predicted and Wmax 
or 6 MWD was found. FFMI was signiﬁ  cantly (p  0.001) 
related to Wmax, but not to 6 MWD In stepwise multiple 
regression analysis Wmax was independently associated with 
height, QF, DLco and age (Table 3). For each 10 Nm decrease 
in QF, Wmax decreased by 2 W and for each 1 mmol.min−¹.
kPa−¹ decrease in DLco, Wmax decreased by 4 W.
6 MWD was associated with height, age, gender, FFM, 
DLco, and QF (Table 3). For each 10 Nm decrease in QF, 
6 MWD decreased by 4 meter, for each mmol.min−¹.kPa−¹ 
decrease in DLco, 6MWD decreased by 12.3 meter and for 
Table 1 GOLD classiﬁ  cation, baseline pulmonary function, health-
related quality of life, dyspnea score, exacerbation frequency, and 
hospitalization
GOLD 2 GOLD 3
Mean SD Mean SD p-value
n (%); 127 (71%) 53 (29%)
n; male (%) ‡ 88 (69 %) 44 (83%) n.s.
Age; yr ∼ 67 ± 9 66 ± 8 n.s.
Current smoker; 
n (%) ‡
40 (31%) 11 (21%) n.s.
Never smoker; n ‡ 8 (6% ) 2 (4%)
Pack years ^ 38 37 n.s.
FEV1 % pred ∼ 67 ± 11 43 ± 5 p  0.001
ITGV % pred ∼ 128 ± 27 150 ± 28 p  0.001
RV % pred ∼ 139 ± 31 171 ± 38 p  0.001
DLco % pred ∼ 72 ± 23 60 ± 18 p  0.001
SGRQ total ∼ 35.7 ± 14.8 43.4 ± 13.7 0.002
SGRQ symptom ∼ 41.8 ± 21.1 46.3 ± 19.6 n.s.
SGRQ activity ∼ 52.7 ± 18.6 62.4 ± 16.1 0.001
SGRQ impact ∼ 23.9 ± 15.1 31.2 ± 16.1 0.004
MRC ∼ 2.6 ± 2.0 2.8 ± 2.0 n.s.
VAS dyspnea ∼ 69.4 ± 13.9 68.5 ± 14.8 n.s.
Exacerbations ^ 1 1.6 1.3 1.2 0.011
Hospital admission ^ 0.14 0.41 0.17 0.43 n.s.
Notes: Data are presented as mean ± SD unless otherwise indicated; ∼ Independent 
Samples T-Test for continuous variables with normal distribution; ^ a nonparametric 
Mann Whitney U-Test; ‡ Chi-Squared Test for categorical variables.
Abbreviations:International Journal of COPD 2008:3(3) 448
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each kg increase in FFM, 6 MWD decreased with 5.1 meter 
(Table 3).
Parameters associated with health-
related QoL in GOLD 2
In univariate analyses QP-60° (p  0.05), QP-180° (p  
0.05), HGF (p  0.01), Pi-max (p  0.05), 6 MWD (p  
0.001), Wmax (p  0.01), and DLco (p  0.01) were sig-
niﬁ  cantly associated with SGRQ total score.
In a stepwise multiple regression analysis, the 6 MWD 
and age were identiﬁ  ed as independent determinants of 
health-related QoL. For each 10 m decrease in 6 MWD, 
SGRQ total score worsened by 0.43 units. The activity 
subscore from the SGRQ was associated with 6 MWD, HGF, 
and age. For each 10 meter decrease in 6 MWD, the activity 
score worsened by 1 unit and for each 10 pounds decrease in 
HGF the activity score worsened with 1.9 units (Table 3).
Parameters associated with 
hospitalization in GOLD 2
Patients with COPD-related hospital admissions during a 
timeframe of 12 months before the start of the INTERCOM 
trial were characterized by a signiﬁ  cantly (p  0.05) lower 
Wmax, QF, HGF, Pi-max than GOLD 2 patients with no 
Table 2 Peak and submaximal exercise response, muscle function, and body composition
GOLD 2 GOLD 3
Mean SD Mean SD p-value
Wmax, W∼ 91.0 ± 30.7 74.2 ± 26.7 p0.001
Vo2 peak, mL/min∼ 1472.8 ± 354.4 1353.2 ± 304 p0.05
Vo2 peak/weight, mL/kg/min∼ 19.2 ± 3.9 18.1 ± 4 n.s
Vco2 peak, mL/min∼ 1535.9 ± 407.4 1329.8 ± 345.6 p0.05
Vco2 peak/weight, mL/kg/min∼ 20 ± 4.8 17.7 ± 4.6 p0.05
RQ peak∼ 1.04 ± 0.1 0.98 ± 0.1 p0.05
PAO2 peak mm Hg∼ 78.2 ± 14.5 64.1 ± 14.4 p0.001
PaACO2 peak mmHg^ 40.2 ± 4.9 44.6 ± 6.6 p0.001
Ve peak, l/min∼ 56.1 ± 15.3 47 ± 12.5 p0.001
Ve reserve, %∼ 16.1 ± 16 0 ± 20.2 p0.001
HR peak, beats/min∼ 130.6 ± 19.6 130.7 ± 18 n.s.
HR reserve, %∼ 14.5 ± 11.4 15.4 ± 10.9 n.s.
6 MWD, m ∼ 525.9 ± 84.9 504.0 ± 102.6 n.s.
CWR-70%, min ^ 14.46 ± 12.33 11.53 ± 8.53 n.s.
Quadr force Nm. ∼ 151.8 ± 47.9 160.1 ± 44.9 n.s.
Quadr force perc. pred ∼ 93.5 ± 22.2 90.1 ± 20 n.s.
Quadr av. power −60° (Watt) ∼ 61.8 ± 22 65.6 ± 22 n.s.
Quadr av. power −180° (Watt) ∼ 104.4 ± 36.5 110 ± 38.1 n.s.
Handgrip force % pred ∼ 77.7 ± 18.8 81.5 ± 14.7 n.s.
Pi-max % pred ∼ 67,1 ± 22.5 63.4 ± 17.8 n.s.
Pe-max % pred ∼ 51.6 ± 18.9 48.8 ± 15.7 n.s.
BMI (kg/m²) ∼ 27 ± 4.4 25.9 ± 4.4 n.s.
FFMI male (kg/m²) ∼ 17.8 ± 1.7 17 ± 1.5 0.01
FFMI female (kg/m²) ∼ 16.9 ± 2.2 16.3 ± 2.2 n.s.
Depletion FFM, n, (%)‡ 19(15%) 11 (21%) n.s.
Nutritional depletion, n (%)‡ 20(16%) 12 (23%) n.s.
FM % weight male ∼ 32 ± 5 32 ± 6 n.s.
FM % weight female ∼ 41 ± 6 44 ± 5 n.s.
Invol. Weight loss n 2 (2%) 0
Notes: Data are presented as mean ± SD unless otherwise indicated. ∼ Independent Samples T-Test for continuous variables with normal distribution; ^ a nonparametric Mann 
Whitney U-Test; ‡ Chi-Squared Test for categorical variables.
Abbreviations:International Journal of COPD 2008:3(3) 449
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hospital admissions. In contrast, no signiﬁ  cant differences 
in FEV1% predicted were found between patients with and 
without hospital admissions. In a logistic regression analysis, 
HGF was an independent determinant of hospitalization 
(Table 4). For each pound increase in HGF, the odds for a 
COPD-related hospitalization decreased with 0.96.
Parameters associated 
with exacerbations in GOLD 2
GOLD 2 patients with exacerbations during a timeframe of 
12 months prior to the start of the study had a signiﬁ  cantly 
(p  0.05) lower DLco, Wmax, QP-60°, QP-180° compared 
with GOLD 2 patients who had no exacerbations, while the 
FEV1% predicted was not signiﬁ  cantly different between 
these groups. However, in a logistic regression analysis FEV1 
was an independent determinant of exacerbations (Table 4). 
For each 100 ml. increase in FEV1 the odds for a COPD-
related hospitalization decreased with 0.90.
Discussion
This study contributes the following novel ﬁ  ndings to our 
knowledge about systemic manifestations of COPD. GOLD 2 
patients with an impaired exercise performance are character-
ized by 1) impaired respiratory muscle function and reduced 
hand grip force but modestly decreased quadriceps strength 
2) below normal fat free mass, particularly in smokers, but 
low prevalence of recent involuntary weight loss. In these 
patients with moderate disease, limb muscle function and not 
airway obstruction was independently associated with exercise 
capacity, and exercise capacity in turn was independently 
associated with health-related QoL. Remarkably, hand grip 
strength as ﬁ  eld marker of skeletal muscle strength was identi-
ﬁ  ed as predictor of COPD-related hospital admissions. These 
ﬁ  ndings strengthen our hypothesis that these patients may 
beneﬁ  t from an interdisciplinary lifestyle program targeted at 
improving exercise capacity and muscle function, education 
and promoting self-management skills but also providing 
Table 3 Multivariate linear regression analyses with Wmax, 6 MWD, SGRQ total score, and SGRQ activity subscore as dependant variable 
in GOLD 2
Dependant variable Wmax* 6MWD** SGRQ total score*** SGRQ activity****
Coefﬁ  cient (SE) p-value Coefﬁ  cient (SE) p-value Coefﬁ  cient (SE) p-value Coefﬁ  cient (SE) p-value
Constant −107 0.017 299 (166) 0.075 120 (25) 0.001 143 (19) 0.001
Height (m) 111 (28) 0.001 349 (102) 0.001 −36 (16) 0.032
QF (Nm) 0.2 (0.05) 0.001 0.4 (0.19) 0.037
DLco(mmol.min−¹.kPa−¹) 4 (1.3) 0.003 12.3 (4.2) 0.004
Age (yr) −0.7 (0.2) 0.004 −3.4 (0.7) 0.001 −0.39 (0.18) 0.05
FFM (Kg) −5.1 (1.2) 0.001
gender 49.8 (18) 0.007
6MWD (m) −0.043 (0.018) 0.017 −0.1 (0.02) 0.001
HGF (pounds) −0.19 (0.07) 0.01
F-statistic 60.7 17.8 9.9 14.8
adjusted R² 0.57 0.48 0.14 0.28
Notes: * Variables removed from the model FEV1, Pi max, HGF, FFM, gender and depletion of FFM; ** Variables removed from the model FEV1, Pi max, HGF, and depletion of 
FFM; *** Variables removed from the model height, gender, QF, DLco, FEV1, Pi max, HGF,   Wmax and depletion of FFM; **** Variables removed from the model height, gender, 
QF, DLco, FEV1, Pi max, Wmax and depletion of FFM.
Abbreviations:
Table 4 Logistic regression analyses with COPD associated hospitalization and exacerbation as dependant variable in GOLD 2
Dependant variable COPD-related hospitalization* Exacerbation**
Coefﬁ  cient (SE) p-value Exp(B) Coefﬁ  cient (SE) p-value Exp(B)
Constant 1.6 (0.94) 0.869 1.168 1.624 (0.872) 0.063 5.072
HGF (pounds) −0.038 (0.17) 0.023 0.963
FEV1 (decilitre) −0.103 (0.048) 0.03 0.902
Notes: * Variables removed from the model Wmax, 6 MWD, height, gender, QF, HGF, DLco, Pi-max, HGF, FFM, and “depletion of FFM”; ** Variables removed from the model 
Wmax, 6 MWD, height, gender, QF, DLco, FEV1, Pi-max, HGF, FFM, and depletion of FFM.
Abbreviations:International Journal of COPD 2008:3(3) 450
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nutritional counseling, smoking cessation counseling and 
psychosocial counseling upon indication.
The cause of gradual but progressive deterioration of skel-
etal muscle function in COPD is largely unknown. Besides 
progressive inactivity, recent studies suggest that systemic 
inﬂ  ammation, measured by highly sensitive C-reactive protein 
(CRP), may trigger exercise impairment (Palange et al 1995; 
Creutzberg et al 2004; Steuten et al 2006; Pinto-Plata et al 
2006; Torres et al 2006). Unfortunately we were not able to 
measure CRP in this study population. The cause of systemic 
inﬂ  ammation in COPD is also unclear. Studies in COPD and 
in other chronic diseases such as cardiovascular disease and 
diabetes indicate that both lungs and extra pulmonary tissues 
could contribute. A common risk factor of these diseases is 
smoking (Baarends et al 1997; Engelen et al 2000). Interest-
ingly, we clearly showed in the group of GOLD 2 COPD 
patients that smokers were characterized by a signiﬁ  cantly 
lower BMI and FFMI compared with exsmokers, which may 
imply an independent effect of smoking on the muscle cell.
As expected, exercise testing showed signiﬁ  cant differ-
ences in the peak performance between GOLD 2 and GOLD 3 
patients due to a more limited ventilatory capacity. More inter-
estingly, no differences in constant workload cycle ergometry 
and 6 MWD was seen between GOLD 2 and GOLD 3 patients. 
This conﬁ  rms that constant workload test is a better measure to 
assess and compare exercise capacity for targeting and evaluat-
ing rehabilitation and lifestyle interventions and probably also 
to characterize impairment in daily life activities.
Our study showed that, also in moderate COPD patients, 
the level of airﬂ  ow obstruction was not a signiﬁ  cant determi-
nant of health-related QoL in contrast to systemic markers 
of disease severity. Our ﬁ  ndings conﬁ  rm that a relatively 
simple 6 MWD (Broekhuizen et al 2006) may be sensitive 
enough to diagnose exercise impairment and the resulting 
reduction in QoL in early stages of COPD without requiring 
exhausting and expensive cycle ergometry.
To our knowledge there are no prior studies that have 
comprehensively investigated exercise impairment in relation 
to disease burden in mild to moderate COPD. The limited 
data available support our results. Hamilton reported that in 
785 patients with mild to moderate obstructive and nonob-
structive pulmonary disease (FEV1 65 ± 15% of predicted) 
and 919 healthy subjects of similar age, average strength 
score was 81% of the reference group and contributed sig-
niﬁ  cantly to exercise impairment (Hamilton et al 1995). Clark 
and colleagues (2000) found in patients with a mean FEV1 
of 77 ± 23% a reduced isokinetic muscle function compared 
with healthy sedentary subjects. Coronell (2004) reported that 
peripheral muscle endurance was impaired in COPD patients 
even in those with relative normal physical activity and mild 
to moderate airﬂ  ow obstruction. This impairment was associ-
ated with an early onset of muscle fatigue and could not be 
predicted from the severity of the disease.
A potential limitation of the present study is a lack of appro-
priate reference values for the various tests. To allow better 
interpretation and comparison with other studies, we therefore 
compared the GOLD 2 patients with the GOLD 3 patients that 
were also enrolled into the INTERCOM trial. While providing 
strong evidence for a lifestyle intervention in this cohort, we 
recognize that our selection criteria limit the external validity 
of the results to the entire group of GOLD 2 patients (as was 
also not intended). The small number of hospitalized patients 
have to be taken into account when considering both the 
internal and external validity of the study. The observation in 
this study nevertheless may have important consequences for 
diagnosis and intervention in patients with GOLD 2 COPD. 
Assessment of 6 MWD (or an adapted walking test), HGF, 
and body composition (bioelectrical impedance analysis) are 
simple ﬁ  eld tests and could be integrated in routine assess-
ment of patients with less severe COPD. The outcome of the 
INTERCOM trial that compares a comprehensive community-
based lifestyle program with usual COPD care, as well as 
other future studies, will inform us about the potential and 
cost-effectiveness of early implementation of interdisciplinary 
lifestyle interventions in less severe stages of COPD.
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